Femasys's three largest insider shareholders as of September 09, 2026 are Kathy Lee-Sepsick (Chief Executive Officer, 360.63K shares), Dov Elefant (Chief Financial Officer, 15.62K shares), Kathy Lee-Sepsick (Chief Executive Officer, 15.62K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kathy Lee-Sepsick | Chief Executive Officer | 15,625 | 0 | 15,625 | 21.4% | 11 Aug, 2026 |
| 2 | Dov Elefant | Chief Financial Officer | 15,625 | 0 | 15,625 | 21.4% | 11 Aug, 2026 |
| 3 | John Dyett | Director | 0 | 14,517 | 14,517 | 19.9% | 17 Dec, 2021 |
| 4 | William Benson Witte | Director | 12,191 | 0 | 12,191 | 16.7% | 17 Dec, 2021 |
| 5 | John Charles Canning | Chief Operating Officer | 4,375 | 0 | 4,375 | 6.0% | 11 Aug, 2026 |
| 6 | Daniel Scott Currie | Chief Operating Officer | 4,314 | 0 | 4,314 | 5.9% | 04 Jun, 2025 |
| 7 | Jeffrey Gerald Mifek | Chief Clinical Medical Affairs | 3,125 | 0 | 3,125 | 4.3% | 11 Aug, 2026 |
| 8 | Jeremy Alexander Sipos | Chief Technology Officer | 3,125 | 0 | 3,125 | 4.3% | 11 Aug, 2026 |
| 9 | Charles Larsen | Director | 3 | 0 | 3 | 0.0% | 04 Jun, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 07 Aug, 2026 | John Charles Canning | Chief Operating Officer | Acquired P | 4,375 | $3.20 | $14.00K | 4,375 | Direct |
| 07 Aug, 2026 | Jeremy Alexander Sipos | Chief Technology Officer | Acquired P | 3,125 | $3.20 | $10.00K | 3,125 | Direct |
| 06 Jul, 2026 | Jeffrey Gerald Mifek | Chief Clinical Medical Affairs | Acquired A | 6,250 | $0.00 | $0 | 6,250 | Direct |
| 24 Jun, 2026 | Kenneth D. Eichenbaum | Director | Acquired A | 880 | $0.00 | $0 | 880 | Direct |
| 24 Jun, 2026 | Charles Larsen | Director | Acquired A | 880 | $0.00 | $0 | 880 | Direct |
| 24 Jun, 2026 | Alistair Milnes | Director | Acquired A | 880 | $0.00 | $0 | 880 | Direct |
| 07 Aug, 2026 | Kathy Lee-Sepsick | Chief Executive Officer | Acquired P | 15,625 | $3.20 | $50.00K | 15,625 | Direct |
| 07 Aug, 2026 | Jeffrey Gerald Mifek | Chief Clinical Medical Affairs | Acquired P | 3,125 | $3.20 | $10.00K | 3,125 | Direct |
| 07 Aug, 2026 | Dov Elefant | Chief Financial Officer | Acquired P | 15,625 | $3.20 | $50.00K | 15,625 | Direct |
| 24 Jun, 2026 | Edward R Uzialko | Director | Acquired A | 880 | $0.00 | $0 | 880 | Direct |
| 07 Aug, 2026 | Kathy Lee-Sepsick | Chief Executive Officer | Acquired A | 15,625 | — | — | 15,625 | Direct |
| 07 Aug, 2026 | Jeffrey Gerald Mifek | Chief Clinical Medical Affairs | Acquired A | 3,125 | — | — | 3,125 | Direct |
| 07 Aug, 2026 | Dov Elefant | Chief Financial Officer | Acquired A | 15,625 | — | — | 15,625 | Direct |
| 07 Aug, 2026 | Jeremy Alexander Sipos | Chief Technology Officer | Acquired A | 3,125 | — | — | 3,125 | Direct |
| 07 Aug, 2026 | John Charles Canning | Chief Operating Officer | Acquired A | 4,375 | — | — | 4,375 | Direct |
| 07 Aug, 2026 | Jeremy Alexander Sipos | Chief Technology Officer | Acquired A | 3,125 | — | — | 3,125 | Direct |
| 07 Aug, 2026 | Jeffrey Gerald Mifek | Chief Clinical Medical Affairs | Acquired A | 3,125 | — | — | 3,125 | Direct |
| 07 Aug, 2026 | Kathy Lee-Sepsick | Chief Executive Officer | Acquired A | 15,625 | — | — | 15,625 | Direct |
| 07 Aug, 2026 | Dov Elefant | Chief Financial Officer | Acquired A | 15,625 | — | — | 15,625 | Direct |
| 07 Aug, 2026 | John Charles Canning | Chief Operating Officer | Acquired A | 4,375 | — | — | 4,375 | Direct |